Rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are representative inflammatory autoimmune diseases thought to involve disturbances in T-and B-cell functions. Immune complexes consisting of antigens and autoantibodies secreted from activated B cells cause severe inflammation in various tissues and organs. To control this inflam
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normalities in B-cell homeostasis, with a decreased proportion of autoreactive memory B cells and reconstitution of B cell lineage after the treatment (4). Therefore, rituximabinduced depletion of memory B cells could also prevent the activation of autoreactive T cells through interactions with B cells, resulting in the down-regulation of CD40 L on CD4 T cells, implying that rituximab may improve the disease
course of RA and SLE by resetting the autoimmune responses (Fig. 3) 
